Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on sympress platform technology.
Let's personalize your content